urokinase

PreclinicalProtein / enzyme

Mmedac GmbH

urokinase is one of 54 small molecule programs targeting Ischemic stroke. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic StrokeActive, not recruiting

Venous ThrombosisActive, not recruiting

Ischemic StrokePreclinical

Active, not recruiting

Venous ThrombosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

119 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Atorvastatin Calcium

Merck & Co.

Phase 3

1 2

PCSK9 Inhibitor

YYun Dai Chen

Phase 3

3 3

Aggrastat

MMedicure

Phase 3

4 4

Zastaprazan

YYonsei University

Phase 3

1 5

Edaravone Dexborneol

SSimcere Pharmaceutical Co., Ltd

Phase 3

10 6

Tenecteplase or Alteplase

IInsel Gruppe AG, University Hospital Bern

Phase 3

2 7

Proamatine

Takeda

Preclinical

2 8

Levaquin

WWim Janssens

Preclinical

3 9

Tylenol

KKenvue Brands

Preclinical

1 10

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Ischemic Stroke

NCT06194968

Clinical

Trials by Indication[1]

Ischemic stroke3 trials

Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset

Completed·GGeneral Hospital of Shenyang Military Region··NCT02854592·4,000 enrolled

Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China

Withdrawn·GGeneral Hospital of Shenyang Military Region··NCT03997292

Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study

Recruiting·TThe First Affiliated Hospital of Zhengzhou University··NCT06194968·1,800 enrolled

Diabetic Foot3 trials

Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia

Terminated·GGWT-TUD GmbH·Phase 3·NCT01638585·34 enrolled

Urokinase Therapy in Diabetic Foot Syndrome

Completed·Mmedac GmbH·Phase 2·NCT00537498·77 enrolled

Urokinase Therapy in Patients With Diabetic Foot Syndrome

Terminated·Mmedac GmbH·Phase 3·NCT00823225·5 enrolled

Randomized Controlled Trial1 trial

Comparison of Standard Versus High Dose Urokinase for Dysfunctional Tunneled Dialysis Catheters in Haemodialysis Patients: a Randomized Controlled Trial

Completed·NNational Healthcare Group, Singapore·Phase 4·NCT06802679·44 enrolled

Thrombectomy1 trial

Local Thrombolytics Before Thrombectomy in STEMI

Unknown status·UUniversity of Roma La Sapienza·Phase 4·NCT01568931·100 enrolled

Empyema1 trial

Urokinase Versus Video-assisted Thoracoscopic to Treat Complicated Parapneumonic Empyema in Childhood

Completed·SSpanish Society of Pediatric Surgery·Phase 3·NCT00798278·200 enrolled

7 more indications

Pleural Empyema1 trial

Dornase Alfa and Urokinase for Kids With Pleural Empyema

Unknown status·AAzienda Ospedaliera di Padova·Phase 2/3·NCT00502632·94 enrolled

Venous thrombosis1 trial

Study of a Novel Thrombectomy Device to Treat Acute Iliofemoral Deep Venous Thrombosis

Unknown status·XXuzhou Medical University·N/A·NCT02414802·40 enrolled

AIN1 trial

Intrapleural Urokinase for Retained Hemothorax

Unknown status·NNational Taiwan University Hospital·Phase 3·NCT01134237·32 enrolled

Brain Aneurysm1 trial

Brain Aneurysms: Utility of Cisternal Urokinase Irrigation

Completed·UUniversity of Valencia··NCT04792944·247 enrolled

Aneurysm1 trial

Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK)

Recruiting·SSecond Affiliated Hospital of Nanchang University·Phase 4·NCT06284642·424 enrolled

Pulmonary Embolism1 trial

Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC)

Completed·—·Phase 4·NCT00968929·83 enrolled

Thromboembolism1 trial

12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China

Completed·—·Phase 4·NCT00799968·129 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for urokinase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — urokinase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for urokinase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — medac GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: Mmedac GmbH

urokinase

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Ischemic stroke3 trials

Diabetic Foot3 trials

Randomized Controlled Trial1 trial

Thrombectomy1 trial

Empyema1 trial

Pleural Empyema1 trial

Venous thrombosis1 trial

AIN1 trial

Brain Aneurysm1 trial

Aneurysm1 trial

Pulmonary Embolism1 trial

Thromboembolism1 trial

References

Drug Info

Quick Facts

Related News